Skip to main content

Table 4 The means of utility scores and relapses avoided rates in RRMS patients using natalizumab and rituximab

From: Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis

Parameters

natalizumab

rituximab

Mean

SD

Mean

SD

Utility Scores

 EDSS 0.0–2.5

0.754

0.186

0.833

0.125

 EDSS 3.0–5.5

0.530

0.120

0.621

0.097

Relapse Rates

 EDSS 0.0–2.5

1.024

1.506

0.313

0.528

 EDSS 3.0–5.5

1.667

1.782

1.727

0.905

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us